

# America's Biopharmaceutical Companies Continue to Expand Advanced Manufacturing Across the United States

Innovative biopharmaceutical manufacturing investments create jobs, grow the U.S. economy and play a leading role in the world's innovation ecosystem. These economic contributions are made possible through robust intellectual property (IP) protections that drive the development of new medicines as well as the technology and processes needed to support manufacturing and distribution.

## Protecting IP Is Essential to Promoting U.S. Competitiveness, Manufacturing and Jobs



IP protections encourage innovation & collaboration



U.S. biopharmaceuticals invest heavily in R&D to develop new medicines for patient needs, technologies & manufacturing



To bring these innovations to patients, U.S. biopharmaceuticals invest in new and upgraded plants and equipment



The U.S. is the global leader in creating & supplying innovative medicines



IP-protected manufacturing advances U.S. competitiveness, creates jobs and grows the economy

## By the Numbers: Major Investments in U.S. Advanced Manufacturing

### TOP 3

The biopharmaceutical industry is consistently in the top three industries investing in U.S. manufacturing.<sup>1</sup>


### 72%

Since 2016, capital investment in biopharmaceutical plants and equipment has increased by over 72%.

### \$126B

The biopharmaceutical industry's total capital investment from 2018-2022 exceeded \$126 billion, second only to motor vehicles.

### Capital Expenditures by Industry, 2016-2022 (\$B)




The biopharmaceutical industry continues to make major R&D investments to develop the advanced manufacturing methods needed to produce and scale the supply of innovative new medicines. U.S. Biopharmaceutical R&D investment grew 58% from 2016 to 2022.<sup>2</sup>

58%



### New Investments Result in More Medicines Made in America




Investments by biopharmaceutical companies are used to build, expand or upgrade facilities to supply the next generation of cutting-edge therapies in America. As companies have added new manufacturing lines and expanded existing ones to increase production capacity, the number of biopharmaceutical manufacturing plants has grown in recent years, now numbering 1,591 facilities across 48 states and Puerto Rico.<sup>3</sup>

## Manufacturing Expansions Across the United States


- Biopharmaceutical investments are being made to expand medicine production in the U.S. and increase manufacturing of supply chain products – strengthening supply chains and mitigating disruptions.
- The map below shows just a few of the U.S. plant announcements or openings since 2022:

### Select U.S. Plant Announcements or Openings since 2022



## Record Exports Support U.S. Manufacturing Jobs

### U.S. Biopharmaceutical Exports Increased 50% since 2020



- Exporting innovative medicines to the rest of the world sustains U.S. jobs and grows the domestic economy at-large.
- Biopharmaceutical exports have grown 50% since 2020 which is good for the American economy. Exports have also continued to grow even after a surge in 2021 in response to the COVID-19 pandemic, reaching an all-time high in 2023.<sup>18</sup>
- Strong IP protections enable this growth, allowing the U.S. to lead the world in developing the advanced manufacturing techniques needed for innovative medicines.


◦ U.S. Export Growth 2008-2023: Biopharmaceuticals 111%, Top Six R&D-Intensive Industries (ex-Biopharma) 11%.<sup>19</sup>




## America's Biopharmaceutical Industry is a Resilient, Sustainable Source of Advanced Manufacturing Job Growth:

- The number of employees working at biopharmaceutical manufacturing establishments grew by 22.1% from 2015 to 2022, to a total of almost 360,000 employees.<sup>20</sup>
- By contrast, overall U.S. manufacturing job growth increased by only 3.8% over the same period.<sup>21</sup>
- While biopharmaceuticals are not immune to economic downturns, this manufacturing-oriented job growth occurred during a recent period of economic contraction – meaning sustainable U.S. employment for manufacturing workers.

**Biopharma Manufacturing Employment, 2015-2022**



**Manufacturing Employment Growth, 2015-2022**



### Sources:

- 1 National Science Foundation. National Center for Science and Engineering Statistics, Business Enterprise Research and Development Survey, 2016-2022. Most recent available <https://nces.nsf.gov/surveys/business-enterprise-research-development/2022>.
- 2 TEconomy Partners LLC. The Economic Impact of the U.S. Biopharmaceutical Industry: 2022 National and State Estimates, May 2024, <https://www.teconomypartners.com/wp-content/uploads/2024/05/The-Econ-Impact-of-U.S.-Biopharma-Industry-2024-Report.pdf>; Research!America. U.S. Investments in Medical and Health Research and Development 2016-2020, [https://www.researchamerica.org/wp-content/uploads/2022/09/ResearchAmerica-Investment-Report.Final\\_January-2022-1.pdf](https://www.researchamerica.org/wp-content/uploads/2022/09/ResearchAmerica-Investment-Report.Final_January-2022-1.pdf)
- 3 NDP Analytics, analysis of U.S. Food and Drug Administration Drug Establishments Current Registration Site, as of April 2024; April 2023; April 2022; February 2021; January 2020; April 2019; April 2018.
- 4 Fierce Pharma, January 9, 2023.
- 5 Fierce Pharma, May 18, 2023.
- 6 EndPoints News, June 7, 2023.
- 7 EndPoints News, July 13, 2023.
- 8 Fierce Pharma, April 17, 2023; BioSpace, May 24, 2024; BioSpace, October 2, 2024.
- 9 Fierce Pharma, March 19, 2024.
- 10 Fierce Pharma, June 6, 2024.
- 11 EndPoints News, June 20, 2024.
- 12 EndPoints News, September 17, 2024.
- 13 Fierce Pharma, June 24, 2024.
- 14 Fierce Pharma, May 1, 2023.
- 15 Fierce Pharma, March 18, 2024.
- 16 Fierce Pharma, October 7, 2024.
- 17 Company press release, October 21, 2024.
- 18 NDP Analytics, analysis of data from U.S. Census. USA Trade Online: Foreign Trade Data. March 2024.
- 19 Ibid.
- 20 TEconomy Partners, LLC. The Economic Impact of the U.S. Biopharmaceutical Industry: 2022 National and State Estimates. May 2024. Report prepared for PhRMA. <https://phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Refresh/Report-PDFs/D-F/The-Econ-Impact-of-US-Biopharma-Industry-2024-Report.pdf>.
- 21 TEconomy ibid.